CTI BioPharma Corp, formerly Cell Therapeutics Inc, develops, acquires and commercializes novel treatments for cancer. The Company's lead product is called arsenic trioxide (Trisenox), which was acquired in January 2000. Trisenox is marketed for patients with a type of blood cell cancer, called acute promyelocytic leukemia, who have relapsed or failed standard therapies. The Company is also developing a new way to deliver cancer drugs more selectively to tumor tissue in order to reduce the toxic side effects and improve the anti-tumor activity of existing chemotherapy agents. In addition, the Company has identified a novel drug target, lysophosphatidic acid acyltransferase (LPAAT-Ã) that, when inhibited, has been shown to reduce tumor cell growth in preclinical models. Cell Therapeutics, Inc. is developing pixantrone, a Phase III single-agent clinical trial product for the treatment of non-Hodgkin's lymphoma and various other hematologic malignancies, solid tumors, and immunological disorders; OPAXIO, a Phase III clinical trial product for the treatment of ovarian, esophageal, and non-small cell lung cancer; and brostallicin, a Phase I/II clinical trials product for the treatment of sarcoma. The company has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.
